BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38289944)

  • 1. A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia.
    Huang T; Leung B; Huang Y; Price L; Gui J; Lau BW
    PLoS One; 2024; 19(1):e0292375. PubMed ID: 38289944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with Fanconi anemia and AML have different cytogenetic clones than de novo cases of AML.
    Rochowski A; Olson SB; Alonzo TA; Gerbing RB; Lange BJ; Alter BP
    Pediatr Blood Cancer; 2012 Nov; 59(5):922-4. PubMed ID: 22517793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.
    Ikeda H; Matsushita M; Waisfisz Q; Kinoshita A; Oostra AB; Nieuwint AW; De Winter JP; Hoatlin ME; Kawai Y; Sasaki MS; D'Andrea AD; Kawakami Y; Joenje H
    Cancer Res; 2003 May; 63(10):2688-94. PubMed ID: 12750298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of IL-3Rα on CD34+CD38- stem cells defines leukemia-initiating cells in Fanconi anemia AML.
    Du W; Li XE; Sipple J; Pang Q
    Blood; 2011 Apr; 117(16):4243-52. PubMed ID: 21330473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia.
    Her Z; Yong KSM; Paramasivam K; Tan WWS; Chan XY; Tan SY; Liu M; Fan Y; Linn YC; Hui KM; Surana U; Chen Q
    J Hematol Oncol; 2017 Oct; 10(1):162. PubMed ID: 28985760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oroxylin A, a natural anticancer flavonoid compound, induces differentiation of t(8;21)-positive Kasumi-1 and primary acute myeloid leukemia cells.
    Hui H; Zhang X; Li H; Liu X; Shen L; Zhu Y; Xu J; Guo Q; Lu N
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1449-59. PubMed ID: 27085528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
    Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
    Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway genes for 4259 patients with myelodysplastic syndromes or acute myeloid leukemia.
    Chang L; Zhang L; Zhao B; Cheng X; Wan Y; Zhang R; Yuan W; Gao X; Zhu X
    BMC Med Genomics; 2023 Nov; 16(1):290. PubMed ID: 37974167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.
    Guinn BA; Schuler PJ; Schrezenmeier H; Hofmann S; Weiss J; Bulach C; Götz M; Greiner J
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.
    Quentin S; Cuccuini W; Ceccaldi R; Nibourel O; Pondarre C; Pagès MP; Vasquez N; Dubois d'Enghien C; Larghero J; Peffault de Latour R; Rocha V; Dalle JH; Schneider P; Michallet M; Michel G; Baruchel A; Sigaux F; Gluckman E; Leblanc T; Stoppa-Lyonnet D; Preudhomme C; Socié G; Soulier J
    Blood; 2011 Apr; 117(15):e161-70. PubMed ID: 21325596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia.
    Mehta PA; Harris RE; Davies SM; Kim MO; Mueller R; Lampkin B; Mo J; Myers K; Smolarek TA
    Cancer Genet Cytogenet; 2010 Dec; 203(2):180-6. PubMed ID: 21156231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells.
    Xie Y; de Winter JP; Waisfisz Q; Nieuwint AW; Scheper RJ; Arwert F; Hoatlin ME; Ossenkoppele GJ; Schuurhuis GJ; Joenje H
    Br J Haematol; 2000 Dec; 111(4):1057-64. PubMed ID: 11167740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations of complementation group, ALDH2 genotype, and clonal abnormalities with hematological outcome in Japanese patients with Fanconi anemia.
    Yabe M; Koike T; Ohtsubo K; Imai E; Morimoto T; Takakura H; Koh K; Yoshida K; Ogawa S; Ito E; Okuno Y; Muramatsu H; Kojima S; Matsuo K; Mori M; Hira A; Takata M; Yabe H
    Ann Hematol; 2019 Feb; 98(2):271-280. PubMed ID: 30368588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical effects of Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45(+) cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice.
    Bergstrom D; Leyton JV; Zereshkian A; Chan C; Cai Z; Reilly RM
    Nucl Med Biol; 2016 Oct; 43(10):635-41. PubMed ID: 27497632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fanconi anemia proteins participate in a break-induced-replication-like pathway to counter replication stress.
    Xu X; Xu Y; Guo R; Xu R; Fu C; Xing M; Sasanuma H; Li Q; Takata M; Takeda S; Guo R; Xu D
    Nat Struct Mol Biol; 2021 Jun; 28(6):487-500. PubMed ID: 34117478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia.
    Ding H; Hashem H; Cabral L; Rangarajan H; Abusin G; Lazarus HM; Abu-Arja R
    Pediatr Transplant; 2017 Mar; 21(2):. PubMed ID: 27976488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How I treat MDS and AML in Fanconi anemia.
    Peffault de Latour R; Soulier J
    Blood; 2016 Jun; 127(24):2971-9. PubMed ID: 27020090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
    Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
    Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLL-CBP fusion transcript in a therapy-related acute myeloid leukemia with the t(11;16)(q23;p13) which developed in an acute lymphoblastic leukemia patient with Fanconi anemia.
    Sugita K; Taki T; Hayashi Y; Shimaoka H; Kumazaki H; Inoue H; Konno Y; Taniwaki M; Kurosawa H; Eguchi M
    Genes Chromosomes Cancer; 2000 Mar; 27(3):264-9. PubMed ID: 10679915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting acute myeloid leukemia through multimodal immunotherapeutic approaches.
    Przespolewski AC; Portwood S; Wang ES
    Leuk Lymphoma; 2022 Apr; 63(4):918-927. PubMed ID: 34818963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.